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1 | INTRODUCTION
There has been a flurry of genomic activity in the United Kingdom,
which has led to expanded discussions regarding feasibility of
national implementation of personalised medicine using genomic
data to guide prescribing. By implementing current scientific
knowledge of pharmacogenes, which influence the pharmacokinetics
and pharmacodynamics of medicines, it would be possible to reduce
the risk of adverse drug reactions and associated morbidity and
mortality, decrease use of less effective drugs in certain individuals,
and increase efficacy of chosen therapeutics, with less guesswork in
dose titration. Where dose changes are indicated, clinical algorithms
which consider pharmacogenetics are increasingly available. To fully
mine the potential of such genomic knowledge, pharmacogenomics
would need to be utilized on a population level. However, this raises a
host of systems-related implementation considerations for which
there is very limited experience in a national context. Multidisciplinary
implementation science has made strides in improving understanding
of how to translate important scientific gains to complex clinical
care systems. Plans to apply pharmacogenomic testing on a large
scale, such as in national health systems, may benefit from such
an approach.1
In this Spotlight Commentary, we discuss several articles recently
published in the British Journal of Clinical Pharmacology, which high-
light the potential for pharmacogenomics actionability within the UK
prescribing sphere, clearly demonstrating scope for improvement in
clinical care.2–4 Global research has also highlighted the importance of
validating the genomic evidence base across diverse groups, which
will be crucial to the ethical implementation of a stratified medicine
programme within the United Kingdom as well as in other nations
across the globe.
2 | PRE-EMPTIVE PHARMACOGENOMICS
POTENTIAL IN UNITED KINGDOM
Providing fuel to the fire for moving towards pre-emptive
pharmacogenomic testing is a recent publication indicating that 80%
of patients were exposed to at least 1 drug associated with an
actionable pharmacogenomic variant over a 20-year period.3 The
researchers looked at exposure to these drugs both retrospectively
(2, 10, and 20 years) and prospectively (5 years) using data from the
Clinical Practice Research Datalink (CPRD). This database includes
anonymized, longitudinal medical records from primary care practices
in the United Kingdom. As a result, the analysis focused on drugs initi-
ated, or continued in primary care and thus does not contain drugs for
specialist indications such as cancer. Kimpton et al. found exposure of
primary care patients to pharmacogenomic drugs to be very common,
with 74% exposed in the 10 years prior and 71% exposed in the
5 years post study initiation.3 The top drugs prescribed were codeine,
omeprazole, simvastatin, lansoprazole, amitriptyline, tramadol,
citalopram, warfarin, paroxetine, and clopidogrel. Several of these
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drugs are the same as those found in a study by Samwald et al. who
analysed prescribing data in the United States between 2009 and
2012 using healthcare administrative claims data.5 From an initial list
of 19 genes with drug/gene pharmacogenomics-based dosing guide-
lines, Kimpton et al. found that just three genes (CYP2D6, CYP2C19,
and SLCO1B1) accounted for virtually all (>95%) pharmacogenomic
drug prescribing across all periods.3 This is in line with the results from
Youssef et al. who found that CYP2D6 accounts for 61.3%, CYP2C19
for 25.0%, and SLCO1B1 for 8.3% of the estimated 5 780 595 medi-
cines prescribed in 2019.2 The study by Kimpton et al. did not look at
genomic data, but noted other studies have shown actionable variants
to be frequently present in these genes.3 This work supports develop-
ment and implementation of a pre-emptive multi-gene pharmaco-
genomics panel to be utilized in a primary care setting to enhance
prescribing decisions based on a patients' genetic background.
3 | MANAGING THE POTENTIAL
DEMANDS OF PHARMACOGENOMIC
SERVICES
The mainstreaming of pharmacogenomic services poses a number of
challenges, not least in meeting the significant demand that could
result if pre-emptive testing were offered routinely in relation to
pharmacogenomic drugs. Youssef et al. estimated that around 4 million
people would need to be tested annually in primary care in the UK.2
Clearly, this may not be practicable, and suitable eligibility criteria will
need to be specified to contain volume and costs. This may involve
prioritizing patients based on other risk factors, limiting testing to situ-
ations where high doses are indicated, or to medicines associated with
the most severe or common adverse drug reactions.
There may be significant advantages in panel tests, where a
number of genes can be assessed simultaneously, and data stored
in patients' electronic health records for when they might be
eligible for a given medicine in the future. Based on Youssef et al.,
a panel test for nine genes (CYP2D6, CYP2C19, HLA-B, SLCO1B1,
CYP2C9, F5, HLA-A, TPMT, and VKORC1) could inform one in
every 11 new prescriptions issued in primary care in the United
Kingdom.2
Challenges to implementing pharmacogenomics may be some-
what different in hospital settings. In the context of more special-
ized care in a children's hospital setting, Mizuno et al. describe how
precision dosing can be achieved by embedding clinical decision
support tools that consider pharmacogenomics, pharmacokinetics,
and pharmacodynamics, within electronic health records.6 They
illustrate applications of pharmacogenomics with examples of medi-
cines with low therapeutic indices—sirolimus, hydroxycarbamide,
methotrexate, and morphine. However, they highlight an important
barrier to more widespread implementation, noting that expertise
spanning relevant clinical pharmacology domains have been
mostly confined to relatively few academic institutions. A wider
adoption of model-informed precision dosing would require more
user-friendly decision support tools.
4 | GLOBAL PHARMACOGENOMICS AND
CHALLENGES TO IMPLEMENTATION
WORLDWIDE
There is continuing interest in studying pharmacogenomics worldwide
and understanding of both ethnic differences and local challenges is
increasing. A recent article reviewed current pharmacogenomics knowl-
edge and clinical adoption in Oceania, Africa, Latin America, and Asia.7
Data from Oceania nicely illustrated local challenges in terms of both
the limited number of pharmacogenes studied to date and the differ-
ences in genetic repertoire between different Pacific regions, as
described previously in more detail.8 These differences have implica-
tions for use of pharmacogenomics in treatment of infectious disease,
particularly malaria, tuberculosis and HIV. Similar problems with phar-
macogenomics implementation in infectious disease treatment exist in
Africa, but the development of the African Pharmacogenomics Consor-
tium may help overcome them. Implementation of pharmacogenomics
in Africa for other drug classes including codeine is already underway,
at least in some hospitals. Warfarin is used widely in Africa, and a sys-
tematic review of genetic factors affecting warfarin dosing in Africans
has recently been completed.9,10 This shows the complexity of factors
affecting dosing, with these factors now being investigated further in
Uganda and South Africa (War-PATH http://warpath.info/) to develop
specific clinical and genetic dosing algorithms in the longer term.
Latin American populations pose special problems for implemen-
tation of pharmacogenomics due to the large degree of population
admixture within the various countries.7 The nature of admixture is
such that even guidelines for pharmacogenomics dosing based on
“continental ancestry” may not be sufficient to deal with the complexity
of population admixture.11 Admixture is likely to also be increasingly
relevant to the United Kingdom and other European countries.
Pharmacogenomics implementation in Asia continues, with one
important local example being implementation of HLA genotyping to
prevent cutaneous adverse reactions linked to anticonvulsants in the
regions where HLA-B*15:02 is common.7 Irinotecan is another
interesting example where treatment-related neutropenia is more
common in those with certain UGT1A1 genotypes. The global
pharmacogenomics article highlights the fact that the allele associated
with decreased UGT1A1 activity phenotype (Gilbert's syndrome)
is different in Asians (UGT1A1*6) compared with Europeans
(UGT1A1*28), but worldwide, the drug label does not mention both
alleles, except in Japan and Singapore.7
Despite these challenges, it is clear that pharmacogenomic testing
is available in a range of countries worldwide, though this availability
is not yet widespread, and implementation is still limited, in both
highly developed and less well-developed regions.12
5 | CONCLUSION
Though challenges must be overcome in pharmacogenomic implemen-
tation on a national and international level, the National Health Ser-
vices in the United Kingdom are uniquely well positioned to lead
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integration of genomic information with mainstream clinical prescrib-
ing. Initiatives from Genomics England and elsewhere across the
United Kingdom in cooperation with the National Health Services will
have the opportunity to proactively address potential barriers to
implementation and drive forward clinical translation of pharmaco-
genomics.13 Pharmacogenomic testing would be recommended in line
with emerging NHS guidance within the United Kingdom and as an
amalgam of existing knowledge as reflected by the PharmGKB
resource globally.14 This has already started with the introduction of
DPYD pharmacogene testing for cancer patients across the United
Kingdom, which may inform altered chemotherapeutic regimes to
decrease risk of toxicity from 5-fluorouracil or capecitabine.4,13
Regulators have a role in increasingly adding pharmacogenomic infor-
mation to summary of product characteristics (SmPC) and updating
prescribing guidance concurrently. In the United Kingdom, for
example, the genetic update to the SmPC was accompanied by a
MHRA safety update on testing for dihydropyrimidine dehydrogenase
(DPD) deficiency prior to prescribing intravenous 5-fluorouracil,
capecitabine, or tegafur.15 Globally driven work highlights the impor-
tance of validating the pharmacogenomics evidence base in diverse
populations, and underlines the fallacy of pure ethnic categories,
therefore mandating a more complex approach to understanding of
ancestry in pharmacogenomics. This will ensure equity in care
resulting from a well-balanced evidence base.
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